Complete Filing Data
Coya Therapeutics, Inc. reported Stockholders Equity of $43.03 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Coya Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | -$21.2M | -$14.9M | -$8.0M | -$12.2M | -$4.9M |
| Research And Development Expense Excluding Acquired In Process Cost | $16.7M | $11.9M | $5.5M | $4.4M | $2.5M |
| Other Nonoperating Income Expense | $1.3M | $1.6M | $639.4K | $63.7K | -$21.5K |
| Operating Income Loss | -$22.6M | -$17.2M | -$7.9M | -$9.8M | -$4.9M |
| Operating Expenses | $30.5M | $20.8M | $13.9M | $9.8M | $4.9M |
| General And Administrative Expense | $11.4M | $8.9M | $7.8M | $4.8M | $2.3M |
| In Process Research And Development | $2.3M | $25.0K | $543.2K | $525.0K | |
| Revenues | $7.9M | $3.6M | $6.0M | $0.00 | |
| Deferred Revenue Current | $1.2M | $848.3K | $923.1K | ||
| Deferred Collaboration Revenue | $1.1M | $945.4K | $574.7K | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$21.2M | -$15.6M | -$7.3M | -$12.2M | |
| Income Tax Expense Benefit | $3.1K | -$720.3K | $723.9K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$2.1M | -$6.1M | -$7.3M | -$4.0M | -$2.9M | -$5.1M | -$3.4M | -$3.1M | -$2.7M | -$4.0M | -$3.4M | -$1.7M |
| Research And Development Expense Excluding Acquired In Process Cost | $2.9M | $3.7M | $5.2M | $2.2M | $4.6M | $3.1M | $1.6M | $1.1M | $1.2M | $1.3M | $1.4M | $978.8K |
| Other Nonoperating Income Expense | $317.1K | $319.5K | $370.2K | $428.9K | $344.4K | $431.1K | $142.1K | $159.0K | $163.6K | $39.4K | $10.9K | -$3.0K |
| Operating Income Loss | -$2.4M | -$6.4M | -$7.7M | -$4.5M | -$3.2M | -$5.5M | -$3.6M | -$3.3M | -$2.9M | -$2.7M | -$3.4M | -$1.7M |
| Operating Expenses | $6.0M | $6.6M | $7.9M | $4.5M | $6.7M | $5.6M | $3.6M | $3.3M | $2.9M | $2.7M | $3.4M | $1.7M |
| General And Administrative Expense | $2.6M | $2.9M | $2.7M | $2.2M | $2.1M | $2.4M | $2.0M | $1.8M | $1.7M | $1.2M | $2.0M | $717.5K |
| In Process Research And Development | $516.0K | $0.00 | $0.00 | $25.0K | $0.00 | $350.0K | $0.00 | $135.0K | ||||
| Revenues | $3.6M | $163.6K | $257.9K | $0.00 | $3.4M | $126.8K | $0.00 | $0.00 | $0.00 | |||
| Deferred Revenue Current | $916.7K | $731.1K | $841.4K | $573.1K | $939.0K | $689.7K | ||||||
| Deferred Collaboration Revenue | $1.1M | $641.2K | $694.4K | $1.2M | $856.7K | $681.3K | ||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$6.1M | -$7.3M | -$2.9M | -$5.1M | ||||||||
| Income Tax Expense Benefit | $0.00 | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $43.0M | $39.6M | $35.6M | -$8.4M | $3.6M | $8.3M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $46.8M | $38.3M | $32.6M | $5.9M | $4.3M | $8.7M |
| Retained Earnings Accumulated Deficit | -$62.0M | -$40.7M | -$25.9M | -$17.9M | -$5.6M | |
| Property Plant And Equipment Net | $11.2K | $38.6K | $65.9K | $93.3K | $120.7K | |
| Prepaid Expense And Other Assets Current | $3.1M | $6.0M | $1.1M | $1.3M | $244.1K | |
| Liabilities Current | $5.9M | $3.8M | $5.1M | $3.8M | $1.1M | |
| Liabilities And Stockholders Equity | $50.0M | $44.3M | $41.3M | $8.4M | $4.8M | |
| Liabilities | $6.9M | $4.8M | $5.6M | $16.8M | $1.1M | |
| Common Stock Value | $2.1K | $1.7K | $1.4K | $259.00 | $259.00 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $8.5M | $5.7M | $26.7M | $1.6M | -$4.4M | |
| Cash And Cash Equivalents At Carrying Value | $46.8M | $38.3M | $32.6M | $5.9M | $4.3M | |
| Assets Current | $49.9M | $44.3M | $41.2M | $7.2M | $4.6M | |
| Assets | $50.0M | $44.3M | $41.3M | $8.4M | $4.8M | |
| Accrued Liabilities Current | $3.6M | $1.4M | $3.0M | $2.0M | $290.8K | |
| Accounts Payable Current | $1.1M | $1.6M | $1.2M | $1.8M | $857.6K | |
| Subscription Receivable In Value | $11.3K | |||||
| Stockholders Equity Note Subscriptions Receivable | $11.3K | |||||
| Conversion Of Convertible Preferred Stock Upon Initial Public Offering | $8.8M | |||||
| Preferred Stock Value | $8.8M | $8.8M | ||||
| Deferred Finance Costs Noncurrent Net | $1.1M | $87.2K | ||||
| Convertible Long Term Notes Payable | $13.0M | |||||
| Collaboration Receivable Current | $7.5M | |||||
| Subscription Receivable Related To Warrant Exercise | $11.3K | |||||
| Payment Of Deferred Financing Costs Related To Initial Public Offering | $113.9K | |||||
| Deferred Financing Costs In Accounts Payable And Accrued Expense | $1.0M | $87.2K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $27.3M | $28.3M | $33.4M | $32.0M | $35.3M | $32.4M | $10.1M | $13.2M | $16.2M | -$5.4M | -$1.4M | $2.0M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $28.1M | $29.8M | $35.5M | $31.1M | $36.6M | $36.0M | $10.9M | $13.1M | $16.3M | $8.7M | $10.4M | $2.3M |
| Retained Earnings Accumulated Deficit | -$56.3M | -$54.1M | -$48.0M | -$37.8M | -$33.8M | -$30.9M | -$27.1M | -$23.7M | -$20.6M | |||
| Property Plant And Equipment Net | $18.1K | $24.9K | $31.7K | $45.4K | $52.3K | $59.1K | $72.8K | $79.6K | $86.5K | |||
| Prepaid Expense And Other Assets Current | $3.9M | $3.7M | $2.8M | $4.4M | $3.3M | $1.3M | $936.4K | $1.3M | $1.0M | |||
| Liabilities Current | $3.7M | $4.5M | $4.3M | $2.3M | $3.8M | $4.3M | $1.8M | $1.2M | $1.3M | |||
| Liabilities And Stockholders Equity | $32.0M | $33.5M | $38.4M | $35.6M | $39.9M | $37.4M | $11.9M | $14.5M | $17.4M | |||
| Liabilities | $4.8M | $5.1M | $5.0M | $3.5M | $4.7M | $5.0M | $1.8M | $1.2M | $1.3M | |||
| Common Stock Value | $1.7K | $1.7K | $1.7K | $1.5K | $1.5K | $1.5K | $996.00 | $996.00 | $996.00 | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$2.8M | $3.4M | $10.4M | -$2.0M | ||||||||
| Cash And Cash Equivalents At Carrying Value | $28.1M | $29.8M | $35.5M | $31.1M | $36.6M | $36.0M | $10.9M | $13.1M | $16.3M | |||
| Assets Current | $32.0M | $33.4M | $38.4M | $35.5M | $39.9M | $37.3M | $11.8M | $14.4M | $17.3M | |||
| Assets | $32.0M | $33.5M | $38.4M | $35.6M | $39.9M | $37.4M | $11.9M | $14.5M | $17.4M | |||
| Accrued Liabilities Current | $1.6M | $2.8M | $1.8M | $1.4M | $1.0M | $2.0M | $1.2M | $983.6K | $724.7K | |||
| Accounts Payable Current | $1.1M | $931.3K | $1.7M | $336.7K | $1.9M | $1.6M | $634.0K | $237.6K | $541.8K | |||
| Subscription Receivable In Value | $149.3K | $11.3K | ||||||||||
| Stockholders Equity Note Subscriptions Receivable | $0.00 | $0.00 | $149.3K | |||||||||
| Conversion Of Convertible Preferred Stock Upon Initial Public Offering | $8.8M | |||||||||||
| Preferred Stock Value | ||||||||||||
| Deferred Finance Costs Noncurrent Net | ||||||||||||
| Convertible Long Term Notes Payable | ||||||||||||
| Collaboration Receivable Current | ||||||||||||
| Subscription Receivable Related To Warrant Exercise | $149.3K | |||||||||||
| Payment Of Deferred Financing Costs Related To Initial Public Offering | ||||||||||||
| Deferred Financing Costs In Accounts Payable And Accrued Expense | $156.5K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $4.3M | $2.7M | $872.2K | $207.3K | $233.2K |
| Net Cash Provided By Used In Operating Activities | -$10.7M | -$10.3M | -$11.2M | -$7.2M | -$3.9M |
| Net Cash Provided By Used In Financing Activities | $20.4M | $16.0M | $38.4M | $9.4M | -$340.6K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$2.9M | $4.9M | -$181.7K | $920.0K | $216.8K |
| Increase Decrease In Accrued Liabilities | $1.1M | -$1.5M | $877.9K | $826.6K | $290.8K |
| Increase Decrease In Accounts Payable | -$527.0K | $477.5K | $298.8K | $845.3K | $665.2K |
| Proceeds From Stock Options Exercised | $38.3K | $2.0K | $89.9K | $158.00 | $317.00 |
| Net Cash Provided By Used In Investing Activities | -$1.2M | -$25.0K | -$543.2K | -$525.0K | -$136.8K |
| Payments To Acquire In Process Research And Development | $1.2M | $25.0K | $543.2K | $525.0K | |
| Increase Decrease In Deferred Revenue | $454.2K | $295.9K | $1.5M | ||
| Proceeds From Issuance Initial Public Offering | $14.3M | ||||
| Increase Decrease In Collaboration Receivable | -$7.5M | $7.5M | |||
| Proceeds From Warrant Exercises | $2.1M | ||||
| Proceeds From Subscription Receivable | $11.3K | ||||
| Proceeds From Issuance Of Common Stock | $20.3M | $14.0M | |||
| Proceeds From Convertible Debt | $10.5M | ||||
| Payments Of Debt Issuance Costs | $997.4K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Share Based Compensation | $1.1M | $435.7K | $180.4K | $21.4K |
| Net Cash Provided By Used In Operating Activities | -$2.8M | $2.1M | -$3.9M | -$2.0M |
| Net Cash Provided By Used In Financing Activities | $19.1K | $1.2M | $14.3M | -$65.2K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$3.1M | $275.4K | -$239.3K | -$191.3K |
| Increase Decrease In Accrued Liabilities | $421.5K | -$844.7K | -$1.3M | -$131.6K |
| Increase Decrease In Accounts Payable | $101.9K | $477.3K | -$270.1K | -$366.5K |
| Proceeds From Stock Options Exercised | $19.1K | $2.0K | $158.00 | |
| Net Cash Provided By Used In Investing Activities | -$25.0K | |||
| Payments To Acquire In Process Research And Development | $25.0K | |||
| Increase Decrease In Deferred Revenue | -$257.9K | -$126.8K | ||
| Proceeds From Issuance Initial Public Offering | $14.3M | |||
| Increase Decrease In Collaboration Receivable | -$7.5M | |||
| Proceeds From Warrant Exercises | $1.4M | |||
| Proceeds From Subscription Receivable | $11.3K | |||
| Proceeds From Issuance Of Common Stock | ||||
| Proceeds From Convertible Debt | ||||
| Payments Of Debt Issuance Costs |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 16.7M | 15.2M | 10.2M | 2.6M | 2.6M |
| Weighted Average Number Of Diluted Shares Outstanding | 16.7M | 15.2M | 10.2M | 2.6M | 2.6M |
| Earnings Per Share Diluted | $-1.27 | $-0.98 | $-0.79 | $-4.73 | $-1.89 |
| Earnings Per Share Basic | $-1.27 | $-0.98 | $-0.79 | $-4.73 | $-1.89 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 7.5M | 7.5M |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 7.5M | 7.5M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 20.9M | 16.7M | 14.4M | 2.6M | 2.6M |
| Common Stock Shares Issued | 20.9M | 16.7M | 14.4M | 2.6M | 2.6M |
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 30.0M |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 7.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 16.7M | 16.7M | 16.7M | 15.2M | 14.9M | 14.5M | 9.9M | 9.9M | 9.7M | 2.6M | 2.6M | 2.6M | |
| Weighted Average Number Of Diluted Shares Outstanding | 16.7M | 16.7M | 16.7M | 15.2M | 14.9M | 14.5M | 9.9M | 9.9M | 9.7M | 2.6M | 2.6M | 2.6M | |
| Earnings Per Share Diluted | $-0.13 | $-0.36 | $-0.44 | $-0.26 | $-0.19 | $-0.35 | $-0.34 | $-0.31 | $-0.28 | $-1.55 | $-1.32 | $-0.66 | |
| Earnings Per Share Basic | $-0.13 | $-0.36 | $-0.44 | $-0.26 | $-0.19 | $-0.35 | $-0.34 | $-0.31 | $-0.28 | $-1.55 | $-1.32 | $-0.66 | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Common Stock Shares Outstanding | 16.7M | 16.7M | 16.7M | 15.2M | 15.2M | 14.6M | 9.9M | 9.9M | 9.9M | ||||
| Common Stock Shares Issued | 16.7M | 16.7M | 16.7M | 15.2M | 15.2M | 14.6M | 9.9M | 9.9M | 9.9M | ||||
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | ||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Depreciation | $27.4K | $27.4K | $27.4K | $27.4K | $16.1K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $207.3K | $233.2K | |||
| Additional Paid In Capital | $105.0M | $80.3M | $61.5M | $681.1K | $473.6K |
| Stock Issued During Period Value Stock Options Exercised | $38.3K | $2.0K | $89.9K | $158.00 | $317.00 |
| Stock Based Compensation Expense And Vesting Of Restricted Stock Units | $4.3M | $2.7M | $872.2K | ||
| Stock Issued During Period Shares Stock Options Exercised | 35.1K | 1.8K | 85.5K | 146.00 | |
| Payment Of Financing Costs Related To Private Placement | $131.9K | ||||
| Exercise Value Of Warrants | $2.1M | ||||
| Conversion Of Convertible Promissory Notes Upon Initial Public Offering | $13.0M | ||||
| Change In Fair Value Of Convertible Promissory Notes | $0.00 | -$2.5M | |||
| Change In Fair Value Of Convertible Promissory Note | |||||
| Amortization Of Financing Costs | $997.4K | ||||
| Stock Issued During Period Value New Issues |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation | $6.8K | $6.8K | $6.8K | $6.8K | $6.8K | $6.8K | $6.8K | $6.8K | $6.8K | $12.5K | $4.0K | $4.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.1M | $1.0M | $1.1M | $775.0K | $435.7K | $262.8K | $191.1K | $69.8K | $44.7K | $21.4K | ||
| Additional Paid In Capital | $83.5M | $82.4M | $81.4M | $69.8M | $69.1M | $63.4M | $37.2M | $36.9M | $36.8M | |||
| Stock Issued During Period Value Stock Options Exercised | $19.1K | $19.1K | $2.0K | $158.00 | ||||||||
| Stock Based Compensation Expense And Vesting Of Restricted Stock Units | $662.3K | $180.4K | ||||||||||
| Stock Issued During Period Shares Stock Options Exercised | 17.6K | 1.8K | ||||||||||
| Payment Of Financing Costs Related To Private Placement | $131.9K | |||||||||||
| Exercise Value Of Warrants | $1.4M | |||||||||||
| Conversion Of Convertible Promissory Notes Upon Initial Public Offering | $13.0M | |||||||||||
| Change In Fair Value Of Convertible Promissory Notes | ||||||||||||
| Change In Fair Value Of Convertible Promissory Note | -$1.4M | $22.3K | ||||||||||
| Amortization Of Financing Costs | ||||||||||||
| Stock Issued During Period Value New Issues | $4.9M | $14.1M |
Most recent annual filing with the SEC: March 16, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.